Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CASINASDAQ:EVOKNASDAQ:MRKRNASDAQ:PMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCASICASI Pharmaceuticals$1.30-3.7%$1.81$1.10▼$7.67$16.54M0.66102,155 shs27,375 shsEVOKEvoke Pharma$2.76-0.2%$3.02$1.94▼$12.32$4.12M0.04124,530 shs5,680 shsMRKRMarker Therapeutics$1.49+3.5%$1.32$0.95▼$5.99$16.29M1.4479,572 shs42,498 shsPMNPromis Neurosciences$0.49$0.53$0.47▼$2.37$15.85M-0.0879,490 shs19,928 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCASICASI Pharmaceuticals+9.35%-8.50%-28.07%-36.26%-64.61%EVOKEvoke Pharma+8.79%-0.72%-24.51%-4.17%-58.93%MRKRMarker Therapeutics+1.41%-4.00%+26.32%+24.14%-69.43%PMNPromis Neurosciences+3.17%-0.61%-3.96%-32.17%-69.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCASICASI Pharmaceuticals3.7932 of 5 stars3.53.00.04.31.11.70.0EVOKEvoke Pharma0.4714 of 5 stars0.05.00.00.00.00.00.6MRKRMarker Therapeutics4.082 of 5 stars3.85.00.03.90.00.80.6PMNPromis Neurosciences1.8812 of 5 stars3.52.00.00.00.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCASICASI Pharmaceuticals 3.00Buy$4.00208.88% UpsideEVOKEvoke Pharma 0.00N/AN/AN/AMRKRMarker Therapeutics 3.50Strong Buy$13.17783.67% UpsidePMNPromis Neurosciences 3.00Buy$4.50827.84% UpsideCurrent Analyst Ratings BreakdownLatest EVOK, MRKR, PMN, and CASI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.005/12/2025PMNPromis NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/9/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.004/1/2025MRKRMarker TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.504/1/2025PMNPromis NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCASICASI Pharmaceuticals$28.54M0.56N/AN/A$0.12 per share10.79EVOKEvoke Pharma$10.25M0.40N/AN/A$4.74 per share0.58MRKRMarker Therapeutics$6.59M2.56N/AN/A$1.73 per share0.86PMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCASICASI Pharmaceuticals-$39.26M-$2.55N/A∞N/A-129.05%-972.55%-77.33%8/15/2025 (Estimated)EVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)Latest EVOK, MRKR, PMN, and CASI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025CASICASI Pharmaceuticals-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million5/12/2025Q1 2025PMNPromis Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A3/31/2025Q4 2024CASICASI Pharmaceuticals-$0.60-$0.79-$0.19-$0.79$7.39 million$13.36 million3/31/2025Q4 2024MRKRMarker Therapeutics-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million3/31/2025Q4 2024PMNPromis Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCASICASI PharmaceuticalsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCASICASI PharmaceuticalsN/A0.810.68EVOKEvoke PharmaN/A1.551.50MRKRMarker TherapeuticsN/A6.796.79PMNPromis NeurosciencesN/A3.363.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCASICASI Pharmaceuticals22.23%EVOKEvoke PharmaN/AMRKRMarker Therapeutics22.39%PMNPromis Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipCASICASI Pharmaceuticals21.24%EVOKEvoke Pharma2.29%MRKRMarker Therapeutics14.50%PMNPromis Neurosciences6.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableEVOKEvoke Pharma41.49 million1.46 millionNot OptionableMRKRMarker Therapeutics6011.31 million9.67 millionNot OptionablePMNPromis Neurosciences532.69 million30.69 millionNot OptionableEVOK, MRKR, PMN, and CASI HeadlinesRecent News About These CompaniesProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 17, 2025 | globenewswire.comComparing ProMIS Neurosciences (NASDAQ:PMN) & Earth Science Tech (OTCMKTS:ETST)June 17, 2025 | americanbankingnews.comProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's DiseaseMay 13, 2025 | nasdaq.comProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | BenzingaMay 13, 2025 | benzinga.comProMIS Neurosciences Announces First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last yearMarch 31, 2025 | markets.businessinsider.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International ConferenceMarch 24, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual MeetingMarch 13, 2025 | globenewswire.comProMIS Neurosciences to Participate in the 37th Annual Roth ConferenceMarch 11, 2025 | globenewswire.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s DiseaseFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trialFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's DiseaseFebruary 25, 2025 | globenewswire.comProMIS Neurosciences Separates With Gavin T. Malenfant as Chief Operating OfficerFebruary 20, 2025 | marketwatch.comProMIS Neurosciences seperates from COO Malenfant, terminates COO positionFebruary 20, 2025 | markets.businessinsider.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Neil Cashman Acquires 15,000 SharesFebruary 13, 2025 | insidertrades.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comFProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comFProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationEVOK, MRKR, PMN, and CASI Company DescriptionsCASI Pharmaceuticals NASDAQ:CASI$1.30 -0.05 (-3.72%) Closing price 03:59 PM EasternExtended Trading$1.27 -0.02 (-1.85%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Evoke Pharma NASDAQ:EVOK$2.76 -0.01 (-0.18%) Closing price 03:56 PM EasternExtended Trading$2.74 -0.01 (-0.54%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Marker Therapeutics NASDAQ:MRKR$1.49 +0.05 (+3.47%) Closing price 04:00 PM EasternExtended Trading$1.46 -0.03 (-2.35%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Promis Neurosciences NASDAQ:PMN$0.48 0.00 (0.00%) Closing price 03:35 PM EasternExtended Trading$0.48 0.00 (0.00%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
